Foghorn Therapeutics announced on Thursday that Lilly had selected its FHD-909 candidate for clinical development.The biotech company explains that Lilly expects to file a clinical trial application.
Health-care companies rose amid promising drug developments. Foghorn Therapeutics shares jumped by 56% after the biotech company said Eli Lilly will conduct.
Foghorn Therapeutics Inc. announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. Lilly plans to file an IND for FHD-909 in Second Quarter.